ImmuPharma PLC says CIDP trial will begin in the second half after meeting with US regulator
ImmuPharma PLC (AIM:IMM, OTC:IMMPF), a specialist drug discovery and development firm, has announced significant progress with its late-stage clinical...
Source: proactiveinvestors.com